References
- 1. Angeli F, Reboldi G, Mazzotta G, et al. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf. 2012;7(1):76-85.
- 2. Dzau V. The cardiovascular continuum and renin-angiotensinaldosterone system blockade. J Hypertens-Suppl. 2005; 23: S9-17.
- 3. Pagliaro P, Penna C. Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther. 2005; 19: 77-87.
- 4. Angeli F, Reboldi G, Poltronieri C et al. Efficacy and safety profile of aliskiren: practical implications for clinicians. Curr Drug Saf. 2014; 9(2): 106-17.
- 5. Sen S, Sabırlı S, Ozyiğit T, Uresin Y. Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials. TherAdv Chronic Dis. 2013; 4(5): 232-41.
- 6. Yoshitomi Y, Kawanishi K, Yamaguchi A, et al. Effectiveness of the direct renin inhibitor, aliskiren, in patients with resistant hypertension. Int Heart J. 2013; 54(2): 88-92.
- 7. Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs. 2007; 67(12): 1767-92.
- 8. Zaporowska-Stachowiak I, Hoffmann K, Bryl W, Minczykowski A. Aliskiren – an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension. Arch Med Sci. 2014; 10(4): 830-6.
- 9. Maibaum J, Feldman DL. Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin Ther Pat. 2003; 13: 589–603.
- 10. Fogari R, Zoppi A. New class of agents for treatment of hypertension: focus on direct renin inhibition. Vasc Health Risk Manag. 2010; 6: 869–82.
- 11. Lizakowski S, Tylicki L, Rutkowski B. Direct renin inhibition – a promising strategy for renal protection? Med SciMonit. 2013; 19: 451–7.
- 12. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007; 370: 221–9.
- 13. McMurray JJV, Pitt B, Latini R et al. Effect of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008; 1: 17.
- 14. Ben-Menachem E, Kyllerman M, Marklund S. Superoxide dismutase and gluthatione peroxidase function in progressive myoclonus epilepsies. Epilepsy Res. 2000; 40: 33-9.
- 15. Naranjan SD, Temsah MR, Netticadan T. Role of oxidative stress in cardiovascular diseases. Journal of hypertension. 2000; 18.6: 655-73.
- 16. Matavelli LC, Siragy HM. Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. J Cardiovasc Pharmacol. 2013; 61(1): 17-22.
- 17. Wen Zhang, Yi Han, GuoliangMeng, et al. Direct Renin Inhibition With Aliskiren Protects Against Myocardial Ischemia/Reperfusion Injury by Activating Nitric Oxide Synthase Signaling in Spontaneously Hypertensive Rats. J Am Heart Assoc. 2014; 3(1): e000606.
- 18. Green, LC, Wagner DA, Glogowski J, Skipper, P.L., Wishnok, J.S., Tannenbaum, S.R. Analysis of nitrate, nitrite and [15 N] nitrate in biological fluids. Anal. Biochem. 1982; 126: 131–8.
- 19. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal, Biochem. 1979; 95: 351–8.
- 20. Pick E, Keisari Y. A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J. Immunol. Methods. 1980; 38: 161–70.
- 21. Auclair C, Voisin E. Nitroblue tetrazolium reduction. In: Handbook of methods for oxygen radical research, (Ed R.A. Greenvvald). 1985; 123–32. CRC Press, Boca Raton.
- 22. Frohlich ED. State of the Art lecture. Risk mechanisms in hypertensive heart disease. Hypertension. 1999; 34: 782–9.
- 23. Weng LQ, Zhang WB, Ye Y et al. Aliskiren ameliorates pressure overload-induced heart hypertrophy and fibrosis in mice. Acta Pharmacol Sin. 2014; 35(8): 1005-14.
- 24. Santuzzi CH, Tiradentes RV, Mengal V et al. Combined aliskiren and L-arginine treatment has antihypertensive effects and prevents vascular endothelial dysfunction in a model of renovascular hypertension. Braz J Med Biol Res. 2015; 48(1): 65-76.
- 25. Savvatis K, Westermann D, Schultheiss HP, Tschope C. First-line treatment of hypertension: critical appraisal of potential role of aliskiren and hydrochlorothiazide in a fixed combination. Integr Blood Press Control. 2010; 3: 163–70.
- 26. Duprez DA, Davis P, Botha J. The Ageless Study: The effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients =65 years of age with systolic hypertension. Circulation.2008; 118: 886–7.
- 27. Stanton A, Jensen C, Nussberger J, O’Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003; 42: 1137–43.
- 28. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005; 111: 1012-8.
- 29. Schmieder RE, Philipp T, Guerediaga J et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. 2009; 119: 417–25.
- 30. Lu H, Rateri DL, Feldman DL et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 2008; 118(3): 984-93.
- 31. Renke M, Lizakowski S, Tylicki L, et al. Aliskiren attenuates oxidative stress and improves tubular status in non-diabetic patients with chronic kidney disease-Placebo controlled, randomized, cross-over study. Adv Med Sci. 2014; 59(2): 256-60.
- 32. Imanishi T, Tsujioka H, Ikejima H, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008; 52(3): 563-72.
- 33. Yamamoto E, Kataoka K, Dong YF et al. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension. 2009; 54(3): 633-8.
- 34. Imanishi T, Tsujioka H, Ikejima H et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008; 52(3): 563-72.
- 35. Kamal S. Aliskiren Augments the Activities of Anti-Oxidant Enzymes in Liver Homogenates of DOCA Salt-Induced Hypertensive Rats. SciRes. 2014; 2: 92-9.